Keystone Symposia
Home | My Account | Shopping Cart  0
  Advanced
  

LANGUAGE NOTE: This meeting will be conducted in English.
Register YourselfRegister a ColleagueSubmit an AbstractSubmit Colleague's AbstractApply for a scholarship


Meeting Program

To view program in "24 hour" time (international) click here.


Sunday, March 22
3:00 - 7:30 PM Registration Foyer
6:30 - 7:30 PM Refreshments Foyer
7:30 - 8:30 PM Keynote Address
Registered attendees for this meeting can view Abstracts for this session starting on 02/22/2009 		Peak 5
William N. Charman, Monash University, Australia
Monday, March 23
7:00 - 8:00 AM Breakfast Summit Gallery
8:00 - 11:00 AM Target Identification and Validation
Registered attendees for this meeting can view Abstracts for this session starting on 02/22/2009 		Peak 5
John H. Adams, University of South Florida, USA
Validation of Blood Stage Targets for Malaria Drug Discovery
Lizbeth Hedstrom, Brandeis University, USA
Targeting a Prokaryotic Protein in Cryptosporidium
Michael A.J. Ferguson, University of Dundee, UK
Targeting Cell-Surface Molecules Responsible for Parasite Survival and Infectivity
Andrew Hopkins, University of Dundee, UK
An Informatics-Based Approach to Target Identification
Short Talk(s) to be Chosen from Abstracts,
9:20 - 9:40 AM Coffee Break Foyer
11:00 AM- 1:00 PM Poster Setup Peaks 1-4
11:00 AM- On Own for Lunch
1:00 - 10:00 PM Poster Viewing Peaks 1-4
2:30 - 4:30 PM Workshop 1: Target Validation: Myths and Reality
 Peak 5
4:30 - 5:00 PM Coffee Available Foyer
5:00 - 7:00 PM Chemical Biology
Registered attendees for this meeting can view Abstracts for this session starting on 02/22/2009 		Peak 5
Leann M. Tilley, La Trobe University, Australia
Role of the Digestive Vacuole in the Action of Endoperoxide Antimalarials
Pradipsinh K. Rathod, University of Washington, USA
Novel Chemistry Underlying Antimalarial Drug Selectivity
Timothy A.J. Haystead, Duke University, USA
Chemoproteomics of the Malaria Kinome
Short Talk to be Chosen from Abstracts,
7:00 - 8:00 PM Social Hour w/ Lite Bites Peaks 1-4
7:30 - 10:00 PM Poster Session 1
Registered attendees for this meeting can view Abstracts for this session starting on 02/22/2009 		Peaks 1-4
Tuesday, March 24
7:00 - 8:00 AM Breakfast Summit Gallery
8:00 - 11:00 AM Compounds
Registered attendees for this meeting can view Abstracts for this session starting on 02/22/2009 		Peak 5
Dominique Mazier, Université Pierre et Marie Curie, France
New Drugs for Liver Stage Malaria
Karl A. Werbovetz, Ohio State University, USA
New Drugs for Kinetoplastids
Paul O'Neill, University of Liverpool, UK
Structure-Activity Studies of Novel Antimalarial Drugs
Rob Don, Drugs for Neglected Diseases Initiative, Switzerland
Drugs for Neglected Diseases
Short Talk(s) to be Chosen from Abstracts,
9:20 - 9:40 AM Coffee Break Foyer
11:00 AM- 1:00 PM Poster Setup Peaks 1-4
11:00 AM- On Own for Lunch
1:00 - 10:00 PM Poster Viewing Peaks 1-4
2:30 - 4:30 PM Workshop 2: Drug Discovery in Academia
 Peak 5
4:30 - 5:00 PM Coffee Available Foyer
5:00 - 7:00 PM Screening
Registered attendees for this meeting can view Abstracts for this session starting on 02/22/2009 		Peak 5
John Lazo, University of Pittsburgh, USA
High Throughput and High Content Screens for Neglected Diseases
Ronald Quinn, Griffith University, Australia
High Throughput Screening of Natural Products
Julie Ann Frearson, University of Dundee, UK
Hit Discovery for Neglected Diseases
Short Talk to be Chosen from Abstracts,
7:00 - 8:00 PM Social Hour w/ Lite Bites Peaks 1-4
7:30 - 10:00 PM Poster Session 2
Registered attendees for this meeting can view Abstracts for this session starting on 02/22/2009 		Peaks 1-4
Wednesday, March 25
7:00 - 8:00 AM Breakfast Summit Gallery
8:00 - 11:00 AM Drug Resistance
Registered attendees for this meeting can view Abstracts for this session starting on 02/22/2009 		Peak 5
Rentala Madhubala, Jawaharlal Nehru University, India
Identification of Potential Biomarkers for Antimony Susceptibility/Resistance in L. donovani
Ric Price, Menzies School of Health Research, Australia
Drug Resistance in Vivax Malaria
Nick PJ Day†, Wellcome Trust-Mahidol University, Thailand
Talk Title to be Determined
Speaker to be Announced,
Short Talk(s) to be Chosen from Abstracts,
9:20 - 9:40 AM Coffee Break Foyer
11:00 AM- On Own for Lunch
2:30 - 4:30 PM Workshop 3: Advantages and Limitations of Preclinical Animal Models
 Peak 5
4:30 - 5:00 PM Coffee Available Foyer
5:00 - 7:00 PM Preclinical Progression
Registered attendees for this meeting can view Abstracts for this session starting on 02/22/2009 		Peak 5
R. Kip Guy, St. Jude Children's Research Hospital, USA
Translational Medicinal Chemistry in Neglected Diseases
Susan Charman, Monash University, Australia
ADME Lead Optimization of Antimalarial Drugs
Reto Brun, Swiss Tropical Institute, Switzerland
Pros and Cons of Rodent Models for Malaria and HAT
Short Talk to be Chosen from Abstracts,
7:00 - 8:00 PM Social Hour w/ Lite Bites Peaks 1-4
8:00 - 11:00 PM Entertainment Peaks 1-4
Thursday, March 26
Departure
      *=Session Chair     †=Speaker invited, not yet responded.


Keystone Symposia would like to thank the sponsor of this meeting for their generous support:




We gratefully acknowledge the companies that provide Keystone Symposia with additional meeting support, including marketing and advertising...

Click here to view these companies

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification and validation of new targets, chemical biology and medicinal chemistry approaches to characterize new compounds, novel screening techniques to identify new chemotypes, mechanisms of drug resistance, and cutting edge strategies to progress new drug candidates into clinical trials. The objectives of this meeting are to discuss current methods to identify and validate new drug targets and to screen libraries of compounds to discover novel chemotypes; assess the potential for chemical biology and medicinal chemistry to optimize compounds that are specific and avoid resistance mechanisms; and identify critical paths for compound progression and to discuss the utility of key models for assessing preclinical drug leads.